Business context and reporting period
This is Trovagene, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 12, 2015. The request metadata names Cardiff Oncology, Inc.; the filing itself identifies the registrant as Trovagene, Inc. and should be matched to the intended issuer before relying on this summary. The filing covers the full fiscal year, with unaudited quarterly results also presented.
Trovagene was developing and commercializing cell-free nucleic-acid diagnostic technology, with its main internal focus on urine-based cancer mutation detection and monitoring. It offered laboratory-developed tests through its CLIA-certified, CAP-accredited San Diego laboratory. The business remained early-stage, with reported revenue primarily from licensing, royalties and milestones.
Financial results and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $280,178 | $259,246 |
| Operating expenses | $15.23 million | $10.95 million |
| Operating loss | $14.95 million | $10.69 million |
| Net loss attributable to common stockholders | $14.35 million | $11.84 million |
| Basic / diluted loss per share | $(0.76) / $(0.88) | $(0.70) / $(0.70) |
| Cash used in operating activities | $12.73 million | $7.32 million |
| Cash and cash equivalents at year-end | $27.29 million | $25.84 million |
| Working capital at year-end | $23.23 million | $24.06 million |
- 2014 revenue comprised $270,178 in royalty income and $10,000 in license fees. The company reported no diagnostic-service revenue to date. Cost of revenue was $15,441; the filing does not present a meaningful overall gross margin for the business.
- R&D expense rose to $6.66 million from $3.95 million; selling and marketing expense rose to $2.73 million from $1.53 million; general and administrative expense rose to $5.81 million from $5.47 million.
- Net investing cash use was $299,790. Financing provided $14.48 million, primarily from a $15 million term loan, partly offset by equipment-line repayments.
- At December 31, 2014, the company reported $15 million of term-loan principal, with $1.90 million current and $13.05 million long-term on the balance sheet. The loan bears 7.07% interest, has interest-only payments through July 2015 and matures July 1, 2018. Contractual obligations including interest totaled $18.36 million.
- After year-end, a February 2015 common-stock offering generated approximately $21.3 million net proceeds. The company reported approximately $46 million cash and $42 million working capital as of February 27, 2015.
Material changes versus the prior period
- Revenue increased by about $21,000, while the net loss attributable to common stockholders widened by about $2.51 million. Higher operating costs more than offset the modest revenue growth.
- Operating cash use increased by about $5.41 million, reflecting the larger operating loss and expanded development and commercialization activity.
- R&D expansion included increasing average internal R&D headcount from nine to 17 and supporting additional clinical collaborations. Selling and marketing costs also increased as the company expanded commercial activity.
- The company obtained $15 million of debt financing in June 2014, contributing to a rise in interest expense to $843,259 from $17,005.
- A $1.43 million gain from remeasurement of warrant derivative liabilities partly offset the 2014 loss; this was a non-operating accounting gain, not operating cash generation.
Outlook, commentary, risks and unusual items
- Management said cash and cash equivalents were expected to fund operations for at least the next 12 months, but also stated that additional capital would be needed to fund development and commercialization beyond that period. No specific revenue, earnings or profitability guidance was provided.
- Management planned to expand clinical evidence, introduce additional laboratory-developed tests, pursue payer reimbursement and consider FDA review for products. The filing said roughly $985,000 of capital equipment investment was expected over the following year.
- Clinical results cited by the company included BRAF assay identification in 29 of 33 enrolled patients at least once, and correlation between urine mutation changes and treatment response in 13 of 17 patients with longitudinal testing. A separate reported KRAS study cited tissue concordance of 95% for evaluable plasma samples and 92% for evaluable urine samples. These are study-specific results, not proof of broad clinical utility or commercial adoption.
- Key risks include continued losses, uncertain adoption and reimbursement, competition, the need for further capital and potential shareholder dilution, regulatory changes affecting LDTs, clinical-study execution and intellectual-property disputes. The $15 million loan is secured by company assets other than intellectual property and includes restrictive covenants and default remedies.
- An anonymous third party opposed claims in a European patent relating to microRNAs and in-vivo cell death; the company said it was considering its options. The filing reported no material pending legal proceedings.
- The company reported $81.4 million in accumulated deficit at year-end. Its deferred tax assets were fully offset by a valuation allowance, and use of tax-loss carryforwards is subject to ownership-change limitations.
- The auditor issued an unqualified opinion on the financial statements and internal controls. Management concluded disclosure controls and internal control over financial reporting were effective at year-end.
Most important facts for investors to verify
- Confirm issuer identity: this filing is for Trovagene, Inc., not Cardiff Oncology, Inc.; also confirm the intended reporting period is fiscal 2014 rather than only 2014 Q4.
- Review audited financial statements and notes for the $15 million debt’s repayment terms, fees, collateral, covenants and future maturities.
- Verify post-offering cash and working capital against subsequent filings, and assess cash burn, financing needs and potential dilution.
- Check current test revenue, test volumes, reimbursement coverage and payer payment rates; this filing reports no diagnostic-service revenue to date.
- Evaluate the size, design and independent validation of clinical studies behind the cited performance results, and the status of regulatory review and patent opposition.